One of our most recent defensive buys cleared a hurdle and its stock jumped

The 10-year Treasury yield retreated 10bps from an intraday high—the highest since April 2022—helping the S&P 500 erase earlier losses, while CME FedWatch pricing put the probability of an October 25bp Fed hike at 29%, down from 68% a week earlier. Cardinal Health and McKesson rose roughly 3%-4% after extending CVS distribution agreements; Cardinal reaffirmed fiscal 2027 adjusted EPS growth of 13%-15% and long-term growth of 12%-14%. Markets will focus on September payrolls, with consensus calling for 90,000 jobs added, 3.2% wage growth and a 4.1% unemployment rate, while reports of a potential pre-Thanksgiving Anthropic IPO at about a $2 trillion valuation support AI-chip sentiment.

Analysis

The distributor re-rating case is less about incremental volume than removal of a left-tail outcome: contract continuity protects purchasing scale, fixed-cost absorption, and specialty-services cross-sell. CAH and MCK should now trade more on execution in higher-margin specialty/healthcare-services businesses than on retail-pharmacy contract speculation. The near-term clearing rally may be largely efficient after a 3-4% move; over 6-18 months, CAH has the cleaner upside if specialty mix expands, while CVS remains the weaker leg because long-duration distribution commitments do not solve its reimbursement, utilization, and retail-profit pressures.

Anthropic-related enthusiasm deserves a credit-adjusted rather than revenue-only read for AVGO. Vendor financing can pull forward accelerator demand and validate custom-silicon economics, but a $42B facility effectively converts part of AVGO's customer concentration into counterparty and funding risk; investors should monitor disclosed guarantees, drawdowns, payment terms, and whether infrastructure commitments translate into recognized revenue rather than contingent backlog. A high-profile IPO would likely lift AI hardware multiples over the next 1-3 months, but it could also expose how much sector demand depends on a small group of cash-burning labs.

The immediate macro trade hinges on payrolls and rates, not the intraday Treasury reversal. A hot wage/employment print can reprice the terminal-rate path within hours and disproportionately pressure long-duration AI semis; a benign report supports a relief rally but does not eliminate supply, inflation, or Treasury-auction risks over the next quarter. The key falsifier for a pro-risk stance is a renewed break higher in the 10-year yield accompanied by rising real yields rather than falling inflation expectations.

Key Decisions for Investors

• Do not chase CAH or MCK on the initial clearing move; accumulate CAH on a 5-8% pullback over 1-3 months if management maintains double-digit EPS growth and specialty-profit targets. Exit or reassess on a material FY guidance cut or evidence that CVS pricing reduced segment margins.
• Run a 6-12 month pair: long CAH / short CVS in equal beta-adjusted dollars. The position isolates distributor scale and specialty-mix execution against CVS's structurally challenged earnings base; target 10-15% relative return, with a stop if CVS demonstrates sustained pharmacy-benefit margin recovery or CAH loses specialty-services momentum.
• Prefer AVGO over NVDA for incremental AI exposure only after verifying the economics and security of Anthropic financing. Use a staged entry following any payroll-driven semiconductor selloff; cap position size because a customer-credit impairment or delayed infrastructure deployment would compress AVGO's custom-chip growth multiple.
• Ahead of payrolls, hedge existing AI-semiconductor beta with short-duration QQQ puts or a tactical short SMH position rather than selling core holdings. Remove the hedge if the 10-year yield fails to sustain a move higher after the data; retain it if real yields rise and rate-cut expectations are pushed out further.